Mega-Merger: Quintiles, IMS Health to Combine
CRO giant and leading healthcare information provider merge to create a wide-ranging R&D-to-commerical services company, in a deal some contend could trigger a trend of larger CROs adding complementary non-clinical offerings.
Quintiles, the world's largest contract research organization (CRO), and information and technology juggernaut IMS Health have agreed to an all-stock merger to create a combined company with service offerings across the entire life sciences product lifecycle-from R&D through commercial to the emerging areas of real-world evidence and patient outcomes. To be officially named Quintiles IMS, the new organization, according to the companies, will boast one of the world’s largest portfolios of healthcare information; deep therapeutic, domain, regulatory, and commercial analytic expertise; and proprietary technology applications supported by more than 50,000 employees operating in 100 countries.
The combined company is worth $17.6 billion based on market capitalization and with $7.2 billion in pro forma revenue in 2015. Industry consultants such as ISR believe this dealmaking trend in the CRO space will likely continue, as the larger CROs look to add complementary services and mid-size companies attempt to quickly gain scale to try to keep up.
Read the full release here.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
